Drugs

SFDA Signs MoC with Saudi Epilepsy Society

2022-04-13

The Saudi Food and Drug Authority (SFDA) signed on April 12, 2022 a memorandum of cooperation (MoC) with the Saudi Epilepsy Society (SES). The MoC aims to promote and develope the professional, research work of professional specialists and educating the community about epilepsy diseases.

The MOC was signed by His Excellency SFDA’s CEO, Dr. Hisham bin Saad Aljadhey, and SES Chairman Dr. Faisal bin Aboud Al-Otaibi.

Other News

News List

RABEZOLE

Warning Date	2022-03-17
Manufacture Company
Warning Reason
Correction Actions
Advices to Consumer

SFDA Suspends Registration and Recalls RABEZOLE Product due to its Lack of Bioequivalence with the Reference Product

2022-03-17

The Saudi Food and Drug Authority (SFDA) has issued a decision to recall and suspend the registration of the product (RABEZOLE) for the two registered strengths of 20 mg and 10 mg, (Registration No 95-368-07 and 96-368-07). The products are marketed by Jamjoom Pharmaceuticals. The decision has been taken as the product was found to be not bioequivalent with the reference product.

To report sector-related issues
Call Centre 19999

Other Warnings

All Warnings

SFDA Detects 19 Facilities Did Not Commit to Providing Pharmaceutical Products to Local Market During January

2022-02-15

The Saudi Food and Drug Authority (SFDA) has detected 19 facilities that violated the Law of Pharmaceutical Establishments and Preparations during January of 2022, due to their lack of commitment to provide pharmaceutical products to the local market.